ZEVASKYN's commercial ramp in ultra-rare RDEB determines whether Abeona can build a self-sustaining rare disease franchise before cash erodes

Bull

QTC network expansion to New York-Presbyterian/Columbia and CHOP adds high-volume academic centers with large RDEB patient populations, potentially accelerating biopsy and treatment cadence materially in H2 2026. Payer coverage at 95% of commercially insured lives removes a major access barrier, and early positive patient experiences at existing sites should drive physician referral networks. If revenue per quarter scales toward $15-20M on six-plus treatments, the path to cash-flow sustainability becomes visible within the planning horizon.

Bear

ZEVASKYN is an autologous cell-gene therapy requiring a biopsy-to-treatment manufacturing cycle, meaning patient throughput is inherently constrained by manufacturing capacity and the mandatory facility shutdown precedent highlights operational fragility. RDEB is an ultra-rare disease with a small addressable population, creating a natural ceiling on the number of eligible patients per year and limiting the revenue ramp slope regardless of commercial execution. If average selling price is pressured by Medicaid mix or if manufacturing yield issues recur, the company could burn through its PRV-generated cash before reaching sustainable revenue.